DGAP-News: aap Implantate AG

aap Implantate AG (XETRA: AAQ) ("aap" or the "Company"), a globally operating medical device company headquartered in Berlin, Germany, today announced that its Management Board is exploring strategic alternatives for more value creation from, among other things, co-development-/license agreements, joint venture agreements to corporate transactions (e.g. merger, share or asset deal, carve out).

This step belongs to the Company's overall current strategic planning and related efforts to explore the full spectrum of possible options to unlock the inherent value of aap's comprehensive trauma product portfolio and its diverse patented platform technologies as well as to build upon its strengthened financial position.

There is no set time table for this process of exploring strategic alternatives. The Company stated that no decision has been made with regard to any alternatives and that there can be no assurance that the Management Board's exploration of strategic alternatives will result in any transaction being entered into or consummated. aap does not intend to discuss or disclose developments with respect to this process until the Management Board has approved a definitive course of action or otherwise concludes the review of strategic alternatives.

_______________________________________________________________________________________
aap Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.